Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 11/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 5/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 5/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 5/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27541930 | 0.97 | CACNA1B (0.58) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL27541957 | 0.92 | CACNA1B (0.55) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL7656853 | 0.92 | CACNA1B (0.53) | CACNA1B | |
| SCHEMBL7665052 | 0.90 | CACNA1B (0.53) | CACNA1B | |
| SCHEMBL4507052 | 0.90 | CACNA1B (0.64) | CACNA1B | |
| SCHEMBL5856296 | 0.90 | CACNA1B (0.71) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5855031 | 0.89 | CACNA1B (0.63) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL27541941 | 0.89 | CACNA1B (0.57) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL27541936 | 0.89 | CACNA1B (0.51) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL27516766 | 0.88 | CACNA1B (0.57) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995179-B2 | Dihydropyridine derivative | AJINOMOTO CO., INC. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20020111494-A1 | Novel dihydropyridine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-15 | — | — | US | disclosed |
| US-6350766-B1 | PAIN, CNS | AJINOMOTO CO., INC. (JP) | 2002-02-26 | — | — | US | disclosed |
| CN-1261348-A | Dihydropyridine derivatives | AJINOMTO CO INC (JP) | 2000-07-26 | — | — | CN | disclosed |
| EP-0985667-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111494-A1 | Novel dihydropyridine derivative | CACNA1B, CACNA1D, CACNA1S | CACNA1B 1/4885CACNA1F 6/4885CACNA1D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.